Precise quantification of extracellular glutamate concentrations upon neuronal activation is crucial for the understanding of brain function and neurological disorders. While optogenetics is an outstanding method for the correlation between distinct neurons and their role in circuitry and behavior, the electrochemically inactive nature of glutamate has proven challenging for recording upon optogenetic stimulations. This difficulty is due to the necessity for using enzyme-coated microelectrodes and the risk for light-induced artifacts. In this study, we establish a method for the combination of in vivo optogenetic stimulation with selective measurement of glutamate concentrations using enzyme-coated multielectrode arrays and amperometry. The glutamatergic subthalamic nucleus (STN), which is the main electrode target site in deep brain stimulation treatment of advanced Parkinson 0 s disease, has recently proven opotogenetically targetable in Pitx2-Cre-transgenic mice and was here used as model system. Upon stereotactic injection of viral Channelrhodopsin2-eYFP constructs into the STN, amperometric recordings were performed at a range of optogenetic stimulation frequencies in the globus pallidus, the main STN target area, in anesthetized mice. Accurate quantification was enabled through a multi-step analysis approach based on selfreferencing microelectrodes and repetition of the experimental protocol at two holding potentials, which allowed for the identification, isolation and removal of photoelectric and photoelectrochemical artifacts. This study advances the field of in vivo glutamate detection with combined optogenetics and amperometric recordings by providing a validated analysis framework for application in a wide variety of glutamate-based approaches in neuroscience.
Glutamatergic neurotransmission is abundant in the brain and is involved in most neurocircuits. Glutamate exerts effects at a submillisecond timescale (Diamond and Jahr 1997) , governing a plethora of physiological processes ranging from synaptic plasticity to neuronal development and degeneration (Picconi et al. 2012; Lee et al. 2016) . As a result of its crucial role in brain homeostasis, dysregulation of glutamate is an important component of brain dysfunction both on the synaptic and network level. For example, pronounced alterations in glutamatergic synaptic transmission is observed upon repeated consumption of drugs of abuse (L€ uscher and Malenka 2011) while overactivity of the glutamatergic system is critical to the generation and propagation of epileptic seizures (Lee et al. 2016) . Furthermore, in Parkinson's disease (PD), maladaptive neurocircuitry changes lead to pathological synchronization of activity from the glutamatergic subthalamic nucleus (STN) to the globus pallidus externa (GPe; globus pallidus, GP in rodents). Desynchronization of this pathological activity is the aim of deep brain stimulation strategies, implemented clinically to relieve symptoms in advanced-stage PD (Picconi et al. 2012) .
The use of optogenetics in transgenic animals has led to an immense leap forward in the understanding of brain function relevant to human conditions (Deisseroth 2014) and in the context of glutamatergic signaling (L€ uscher et al. 2015) . By implementing Cre-driven expression of light-gated ion channels and pumps, so called opsins, optogenetic stimulations can be regulated in a precise spatiotemporal manner in vivo (Han 2012 ). Nevertheless, a major gap remains between the optogenetic stimulation and any behavioral consequences recorded upon this intervention, such as neurotransmitter responses immediately within local synapses and on network level. Furthermore, as a result of the abundance of glutamatergic neurotransmission in the brain, secondary glutamatergic activation might occur even in cases in which glutamatergic neurons were not the target of the optogenetic intervention. This is especially important in studies that investigate behavioral alterations in response to optogenetic stimulation, where neuronal activation and neurotransmitter concentrations are not directly monitored.
Closing the gap between behavioral responses following optogenetic stimulation and the underlying physiological process requires a technique able to dependably quantify glutamate release in vivo. While microdialysis allows direct measurements of neurotransmitter output in response to optogenetic stimulation, this method does not provide sufficiently high spatial-and temporal resolution to be useful for studying the rapid phasic activity of glutamate (Zant et al. 2016) . Patch-clamp electrophysiological recordings provide invaluable insights into the function of glutamatergic synaptic transmission at a high temporal resolution and are widely used in conjunction with optogenetic stimulation (Fiala et al. 2010) . However, they cannot be used to quantify extracellular concentrations as they rely on currents elicited intracellularly in post-synaptic cells. In contrast, in vivo amperometry using enzyme-coated microelectrodes combines the ability to quantify extracellular neurotransmitter levels seen in microdialysis with a high spatial and a temporal resolution equal to electrophysiological recordings. This method thus allows for real-time measurements of both phasic-and tonic neurotransmitter release and enables elucidation of the role of phasic glutamate release upon pharmacological manipulations (Burmeister and Gerhardt 2001; Konradsson-Geuken et al. 2009 and during behavioral activity (Wassum et al. 2012; Malvaez et al. 2015) . Based on these parameters, in vivo amperometry should be particularly well suited for quantification of optogenetically evoked glutamate release.
In this study, we establish a method for recording glutamate concentrations upon optogenetic stimulation using glutamate-sensitive multielectrode amperometry in the intact neurocircuitry of adult mice. We utilized the Pitx2-Cre transgenic mouse line which allows for selective expression of optogenetic viral constructs in glutamatergic neurons of the STN (Skidmore et al. 2008; Schweizer et al. 2014 Schweizer et al. , 2016 . Consequently, we were able to quantify optogenetically evoked glutamate release from Pitx2-Cre-expressing synaptic terminals in the GP of anesthetized mice, isolate light artifacts and detect glutamate release not originating from opsin activity. This novel combination of optogenetic stimulation and amperometry in the intact rodent brain provides the means for physiological insight into the importance of glutamate release and could thus be useful for future studies of glutamate transmission in the context of neurological and neurodegenerative diseases.
Material and methods

Ethical statement
All mice used in the study were housed in the animal facility at Uppsala University, Uppsala, Sweden, in accordance with the Swedish regulation guidelines (Animal Welfare Act SFS 1998:56) and European Union legislation (Convention ETS123 and Directive 2010/63/EU). Ethical approval was obtained from the Uppsala Animal Ethical Committee (reference numbers C156/14; C138/15). The animals were housed separated by sex in standard macrolon cages (59 9 38 9 20 cm) with aspen wooden bedding (Scanbur AB, Sollentuna, Sweden) and cage enrichment. Animals were maintained in a temperature (21-22°C) and humidity (45-55%) controlled facility on a 12 : 12-h light/dark cycle (lights on at 7AM). Experiments were carried out during the light cycle. The animals had ad libitum access to food (R36, Labfor; Lactamin, Vadstena, Sweden) and water. Animals used in this study were Pitx2-cre tg/wt mice (Targeted L-Glutamate oxidase (GluOx; EC 1.4.3.11) was purchased from Nordic Biosite (T€ aby, Sweden). All solutions were prepared using filtered and deionized water. The adeno-associated virus serotypes DJ and 5 (AAV-DJ and AAV5) were purchased from UNC Vector Core, University of North Carolina (USA).
Stereotactic virus injections
Adult (> 8 weeks) Pitx2-Cre tg/wt mice, weighing at least 20 g were anesthetized with isoflurane (isoflurane with air (0.5-2 L/min, 1-3% v/v) and mounted in a stereotaxic apparatus. Mice were treated with the local anesthetic bupivakain (0.1 mL of a 2 mg/mL solution) on the site of the incision. About 30 min before the surgery and 24 h post-operation, the mice were treated with 5 mg/kg carprofen i.p. for pain relief. A bilateral injection of AAV channelrhodopsin 2 (ChR2)-EYFP [AAV-DJ-EF1a-DIO-hChR2-EYFP (n = 11)] or ChR2-lacking [AAV-DJ-EF1a-DIO-EYFP (n = 4), AA5-EF1a-DIO-EYFP (n = 2)] vector (1 9 10 12 vector genome/mL; UNC Vector Core Facility, Chapel Hill, NC, USA) was made into the STN using a NanoFil syringe with 35-gauge needle (World Precision Instruments, Sarasota, FL, USA). Injections were performed at two dorsoventral (DV) levels with the following coordinates: anterioposterior (AP): À1.9 mm from bregma, mediolateral (ML) from midline: AE1.7 mm, and DV from bregma: À4.75 and À4.25 mm (injection rate: 0.10 mL/min, a total of +0.25 lL/coordinate) according to Paxinos and Franklin (2012) . The injection needle was left in place for 10 min after the last injection and then slowly removed. The animals were allowed to recover for at least 4 weeks before being introduced in any experiment. No randomization was performed to determine the virus injected for each individual mouse to avoid cross-infection between individual mice injected with different constructs (Reuter et al. 2012) . Sample size for each group was determined based on that of previous studies utilizing in vivo amperometry with enzyme-coated microelectrodes (Day et al. 2006; Konradsson-Geuken et al. 2009 Mishra et al. 2015) . No sample size calculations were performed.
In vitro calibration of glutamate-sensitive microelectrodes Prior to calibration, m-PD (5.0 mM) was electropolymerized onto all sites of the microelectrode to reduce access of potential electrochemically active interferents, e.g. AA and catecholamines, to the platinum recording sites (Day et al. 2006; Rutherford et al. 2007; Konradsson-Geuken et al. 2009 Mishra et al. 2015) .
The electroplating was performed in 0.05 M nitrogen-saturated phosphate-buffered saline (PBS, 40 mL, pH 7.4) at 20°C, using the FAST-16 electroplating tool (Quanteon; LLC, Nicholasville, KY, USA), peak-to-peak amplitude of +0.25 V at 0. ) were calculated. The microelectrodes to be used for implantation and further in vivo recordings had to fulfill the following calibration criteria: (i) similar background current in the glutamatesensitive and sentinel channels, (ii) linear response to increasing concentrations of glutamate (R 2 close to 1), (iii) a minimum glutamate sensitivity of À3 pA/lM glutamate, (iv) a limit of detection of ≤ 0.5 lM, and (v) a high selectivity for glutamate over AA (i.e., ˃ 50 : 1). The in vitro calibration data for all electrodes used is summarized in Supplementary Table S1 .
In vivo amperometric measurements
The microelectrode consists of a ceramic paddle with four platinum recording sites (15 9 333 lm). The four sites are arranged in two pairs beginning approximately 100 lm from the electrode tip. To design a glutamate sensitive microelectrode, one pair of recording sites was manually coated under a microscope with a mixture of GluOx (0.5 unit/1 lL), 1% BSA and 0.125% glutaraldehyde in H 2 O. The remaining pair was coated only with BSA and glutaraldehyde to serve as control channels (sentinel), sensitive to the oxidation of all endogenous molecules other than glutamate. This specific coating of the microelectrode allows for self-referenced recordings in which the current derived exclusively from glutamate oxidation can be isolated (Day et al. 2006; Rutherford et al. 2007; Konradsson-Geuken et al. 2009 Mishra et al. 2015) . Enzyme-coated microelectrodes were allowed to cure for at least 48 h at 20°C before any further use. Briefly, the released glutamate is oxidized by GluOx at the glutamate-sensitive sites, generating a-ketoglutarate and H 2 O 2 . As the microelectrode is maintained at a constant potential (+0.7 V vs. an Ag/AgCl reference electrode), the H 2 O 2 reporting molecule is further oxidized, yielding two electrons. The resulting current is then amplified and recorded with a FAST-16 recording system (Quanteon; LLC) at a recording frequency of 10 Hz. Extracellular glutamate reaches the platinum surface of sentinels (without GluOx), but no oxidation current is generated. Therefore, any current detected at these sites is as a result of electrochemically active molecules other than glutamate or electrical interference. At a holding potential of +0.25 V, glutamate oxidation by the GluOx enzyme still occurs, the H 2 O 2 reporting molecule generated in this reaction is, however, not further oxidized at this potential. Hence, no currents derived from glutamate oxidation are recorded at this potential (Day et al. 2006) . This was used as a control to detect and isolate possible artifacts remaining after self-referencing. An optical fiber with a tip diameter of 250 lm was mounted on the back of the microelectrode at a distance of 80 lm from the electrode tip. The tip of the optical fiber was beveled at a 45°angle facing away from the microelectrode. The distance of the optic fiber to the electrode tip was confirmed pre-and post-experiment and no differences in the distance were detected. Surgeries were carried out in mice deeply anesthetized with isoflurane [isoflurane with air (0.5-2 L/min, 1-3% v/v)] and treated with the local anesthetic marcain bupivakain (0.1 mL of a 2 mg/mL solution). The recordings complex consisting of the microelectrode and optical fiber was implanted in the GP at AP: À0.22 mm from bregma, ML: À1.4 mm from midline and DV À3.24 mm from dura (Figure 1 a,b) .
Pressure ejections of 0.25 lM exogenous glutamate from borosilicate pipettes were carried out using a Picospritzer (Parker Hannifin, Cleveland, OH, USA).
Laser stimulation
Laser stimulations were carried out using a MBL-III-473 nm-100 mW laser (CNI Lasers, Changchun, China) connected to an optical fiber at an output power of 4 mW during constant stimulation, resulting in an illumination strength of 81.5 mW/ mm 2 . The relative output power (P rel ) was calculated by multiplying the power during constant light stimulation with the duty cycle of the stimulation. The laser was controlled by an Arduino UNO microcontroller which was furthermore used to signal timing of the stimulations to the recording software. The program used to control the stimulation and a circuit diagram of the connections is accessible in Supplementary Data S1 and Figure S1 .
Data analysis
The analysis of recorded raw data was performed using FAST analysis 6.1 program (Jason Burmeister Consulting, LLC, USA). As electrical interference will be measured both in enzyme-coated and sentinel sites, while glutamate signals are only recorded as a result of oxidation on the enzyme-coated sites, the signal recorded from one sentinel channel was subtracted from the signal of one glutamate-sensitive channel to obtain the signal used for all further calculations. Based on the in vitro calibration carried out immediately before the surgery, the recorded signal was converted from current measured to an equivalent glutamate concentration. The baseline signal was calculated as the mean signal of the 30 data points preceding each stimulation. For each protocol and frequency, the mean of the concentration amplitudes of all five consecutive stimulations recorded at +0.7 V (Ĉ 0.7 ) and +0.25 V (Ĉ 0.25 ) was calculated.
The amplitude of the concentration of glutamate (Ĉ glu ) released during each frequency in protocol A and B was then calculated as
The amplitude/artifact ratio (AR), the ratio of the amplitude at +0.7 V and +0.25 V holding potential was calculated as
The equivalent glutamate concentration evoked per ms of active laser stimulation (DC/t) was calculated as
Signal analysis and processing was performed using a customwritten script in R (The R Project for Statistical Computing). C baseline was calculated as the mean of 30 data points (3 s) recorded prior to the onset of the stimulation. Averaged signals of C 0.7V and C 0.25V were obtained by subtracting C baseline from the recorded signal for each stimulation in a given animal to obtain a normalized signal for each recording. In subsequent steps, all stimulations of the same stimulation frequency f stim in the same animal, holding potential and protocol were averaged to generate the normalized signal of each experimental condition per animal. The average signal of all animals was then calculated for C 0.7V and C 0.25V . Based on these values, the corrected glutamate signal C glu was calculated as:
Statistical analysis was performed using a custom-written script in R (The R Project for Statistical Computing).
These data were normally distributed for all groups (ShapiroWilk normality test). Differences between experimental conditions and groups were performed using repeated-measures ANOVA and the Tukey HSD test. All values are reported as mean AE SEM. The SEM. was calculated on the basis of the composite standard deviation of all repetitions of the same f stim in the same animal and protocol.
The signal processing and statistical analysis scripts, all raw data files as well a full report on the results of the statistical analysis and a brief description on the use of the scripts can be found in Supplementary Data S2.
Histological verification
Immediately after the amperometric recordings, each mouse was sacrificed by cervical dislocation whereupon the brain was dissected and post-fixed for 24 h at +4°C. 100 lm thick sections were prepared using a vibrating blade microtome (Leica VT 1200S; Leica Microsystems, Stockholm, Sweden) and analyzed for eYFPexpression using a fluorescence microscope (Leica CTR 6000; Leica Microsystems). Placement of the recording complex within the GP was confirmed for all animals (Fig. 1i) . 
Exclusion criteria
The following exclusion criteria were set for each experiment: (i) Only experiments in which recordings at both +0.7 and +0.25 V were carried out, were included in the analysis. If an animal died before the experiment was completed, the entire experiment was excluded, (ii) Only recordings from mice with confirmed expression of the AAV construct in the STN and GP were used for the analysis, (iii) If an infection of the skull bone was visible in the mice during the stereotactic surgery, the mouse in question was sacrificed immediately and no implantation carried out, (iv) If the distance of the optic fiber changed during the recording, the experiment in question was excluded from the analysis.
In the group injected with the ChR2-eYFP construct, two mice died during the experiment, before a stable baseline could be established. An additional two mice in this group lacked expression of the ChR2-eYFP construct in the STN and GP and were excluded. No infections or movements of the optical fiber post-recordings were detected in any of the mice. A total of n = 7 mice were included for the ChR2-eYFP group as well as n = 6 mice in the eYFP control group lacking ChR2.
Results
The Pitx2-Cre transgenic mouse line (Skidmore et al. 2008) allows for expression of ChR2-containing optogenetic viral constructs selectively within the STN and its efferent projections (Schweizer et al. 2014 (Schweizer et al. , 2016 . This transgenic mouse line was therefore selected for establishing amperometric recordings of glutamate release upon optogenetic stimulation. The experimental setup was as follows: Adult Pitx2-Cre tg/wt mice were stereotactically injected with an optogenetic construct bilaterally into the STN and allowed to recover for at least 4 weeks. Recording electrodes were coated 48 h prior to amperometric recordings. On the day of the amperometric experiment, recording electrodes were electroplated, calibrated, mounted with an optic fiber and implanted stereotactically in the GP of anesthetized mice (Fig. 1a) .
Injections were performed with AAV containing a doubleinverted construct of either ChR2-(H134R) fused with the fluorescent reporter eYFP (ChR2-eYFP, n = 7) or the eYFP reporter alone (eYFP, n = 6) bilaterally into the STN (Fig. 1b) . In the ChR2-eYFP group, all mice were injected with viruses of the AAV-DJ serotype, while both AAV-DJ (n = 4) and AAV5 (n = 2) were used in the eYFP group. No apparent expression differences were detected between the two serotypes and the results were thus combined in the analysis. Ample eYFP-derived fluorescence was seen in cell bodies of the STN (Fig. 1c) and projections leading to the GP (Fig. 1d) .
Four-channel self-referencing microelectrodes consisting of two glutamate-sensitive channels coated with GluOx, and two sentinel channels lacking GluOx were used to quantify glutamate concentrations (Fig. 1e) . GluOx oxidizes released glutamate to a-keto-glutarate and H 2 O 2 on the surface of the glutamate-sensitive channels. When a constant potential of +0.7 V versus a reference electrode is applied, the generated H 2 O 2 will be further oxidized, yielding 2 electrons that can be measured using amperometry (Day et al. 2006; Konradsson-Geuken et al. 2009 Mishra et al. 2015) . Prior to the experiment, the microelectrode was calibrated in vitro with ascorbic acid, increasing concentrations of glutamate followed by dopamine and H 2 O 2 (Fig. 1f) . The results of the in vitro calibration are summarized in Table 1 and Supplementary Table S1 . The selectivity of the electrodes used for the ChR2-eYFP group were slightly lower than those of the eYFP control group, however not significantly so (unpaired t-test, p = 0.086). To reduce artifacts due to electric currents generated from direct light irradiation onto the platinum electrode (Han 2012), we created an optic fiber with a 45°tip angle facing away from the microelectrode and placed it on the back of the microelectrode at a distance of 80 lm from the electrode tip (Fig. 1g) . At this tip angle, the emitted light on the tip spreads as depicted in Fig. 1(g) (Davenport et al. 2016) . The recording complex consisting of the optic fiber and microelectrode was stereotactically implanted in the GP of anesthetized mice ( Fig. 1h and i) . Basal glutamate levels of C baseline = 3.92 AE 1.22 lM were recorded in the GP before the first optogenetic stimulation (n = 12). At a holding potential of +0.7 V, glutamate oxidation-derived H 2 O 2 can be further oxidized on the electrode surface, enabling recording of glutamate release on the glutamatesensitive channels (Fig. 1j, top) . In contrast, at a holding potential of +0.25 V, H 2 O 2 oxidation does not take place and no glutamate release is detected on the glutamate-sensitive channels (Fig. 1j, bottom) . This can be used to control for possible artifacts underlying the recorded signal (Day et al. 2006 ).
Raw signals generated at different holding potentials
The first stimulation protocol, from here on referred to as protocol A, was designed to produce phasic laser stimulation with a duration of t stim = 1 s at increasing f stim of 10, 20, and 40 Hz resembling physiological activity in the theta (8-12 Hz) beta (12-35 Hz) and gamma (40-70 Hz) ranges, commonly observed in the STN (Bevan et al. 2002; Zavala et al. 2015) . We performed five repetitions separated by 30 s for each frequency (Fig. 2a and b) . To evaluate the influence of optogenetic stimulation with increasing intensities, we applied the stimulation with a t pulse of 5 ms for each frequency, yielding increasing duty cycles of 5% for 10 Hz, 10% for 20 Hz, and 20% for 40 Hz. The resulting relative powers P rel of the stimulations were then 0.2 mW for 10 Hz, 0.4 mW for 20 Hz, and 0.8 mW for 40 Hz. Stimulations were first carried out at a holding potential of +0.7 V, where glutamate oxidation-derived H 2 O 2 can be oxidized on the electrode surface, enabling recording of glutamate. As opposed to local chemical stimulation, for example, KCl, which is briefly administered for a fraction of a second, ::ChR2-eYFP mice,Ĉ 0.7V was significantly higher thanĈ 0.25V and theĈ increased with increasing f stim . The frequency-dependent increase was different at +0.7 V and +0.25 V. n = 7 ChR2-eYFP, n = 6 eYFP controls. Twoway repeated-measures ANOVA: ###p < 0.001. optical stimulation in this study, is carried out over the period of one second. Therefore, we expected light artifacts to possibly be evoked by our stimulation. The first step in our analysis was thus to detect any such artifacts and separate them from glutamate-derived signals. This analysis focused mainly on the ChR2-eYFP group; the corresponding data from the eYFP group are summarized in Supplementary Figure S2 .
During the optogenetic stimulation protocol A at +0.7 V, we detected a signal at the glutamate-sensitive channel and a smaller signal at the sentinel channel. Subtraction of the sentinel from the glutamate-sensitive channel, yielded an isolated signal with reduced noise (Fig. 2c upper left) , which was used for all further calculations. Interestingly, part of the signal on both the glutamate-sensitive and sentinel channel remained at +0.25 V (Fig. 2c lower left) . Increasing frequencies of stimulation resulted in higher P rel of the laser stimulation and thus evoked larger signals both at +0.7 and +0.25 V (representative example in Fig. 2d ) in the ChR2-eYFP group. The peak concentrationĈ was calculated and the means of all five stimulations for each frequency computed at the two holding potentials asĈ 0.7V and C 0.25V .Ĉ 0.7V was significantly higher thanĈ 0.25V and increased with higher f stim (two-way repeated-measures ANOVA holding potential effect: F = 45.36, p < 0.001; frequency effect: F = 36.48, p < 0.001; interaction holding potential and frequency: F = 35.55, p < 0.001) (Fig. 2d and e).
ChR2-independent component contributing to local glutamate concentrations As the signal evoked by optical stimulation at +0.7 V consisted of two components, a large glutamate response dependent on the holding potential, and a smaller component that persisted even when reducing the holding potential to +0.25 V where no H 2 O 2 oxidation occurs, we reasoned that the component remaining at +0.25 V was likely an artifact brought about by the light stimulation itself rather than glutamatergic signaling. We were thus interested in separating the glutamate concentration evoked by optogenetic stimulation from the artifact, which we achieved by subtracting the signal obtained at +0.25 V from the signal obtained at +0.7 V (Fig. 3a) .
Peak glutamate concentrationĈ glu was calculated using formula (1). The ChR2-eYFP group possessedĈ glu of 0.27 AE 0.08 lM at f stim = 10 Hz, 0.41 AE 0.06 lM at f stim = 20 Hz and 0.92 AE 0.04 lM at f stim = 40 Hz, which represents the actual concentration of glutamate released in response to optogenetic stimulation at that frequency.
To determine if all glutamate released during stimulations originated from ChR2 activation, we compared the peak concentration of the ChR2-eYFP group with the one elicited in the eYFP group. The eYFP group displayed overall significantly lowerĈ glu than the ChR2-eYFP group (two-way repeated measures ANOVA viral construct: F = 10.00, p < 0.01; frequency: F = 63.50, p < 0.001; interaction viral construct and frequency: F = 6.21, p < 0.01), with 0.08 AE 0.04 lM at f stim = 10 Hz, 0.22 AE 0.03 lM at f stim = 20 Hz and 0.44 AE 0.04 lM at f stim = 40 Hz (Fig. 3a and b) .
Post-hoc statistical analysis pinpointed the significant difference inĈ glu to f stim = 40 Hz (Tukey's HSD eYFP 10 Hz: ChR2-eYFP 40 Hz, p < 0.001; eYFP 20 Hz: ChR2-eYFP 40 Hz, p < 0.001; eYFP 40 Hz: ChR2-eYFP 40 Hz, p < 0.01) (Fig. 3b) while the differences were not significant at f stim = 10 and 20 Hz. The absence of a significant difference inĈ glu at low stimulation intensities could point to an incomplete activation of ChR2 at these stimulation parameters. As the size and shape of the elicited signal was, however, different in the ChR2-eYFP and eYFP groups at all frequencies, we chose to analyze additional parameters.
We calculatedĈ 0.7 in relation toĈ 0.25 in the different groups to determine AR using formula (2). The AR enabled us to compare the amount of glutamate released in response to optogenetic stimulation with the light-induced artifacts produced under the same conditions. It thus provided a means to compare stimulations and glutamate responses over a wide range of different absolute concentrations.
The ChR2-eYFP group displayed significantly larger AR than the eYFP group (two-way repeated-measured ANOVA viral construct: F = 8.88, p < 0.05). No statistical difference was seen over the different frequencies in either group (two-way repeated-measures ANOVA frequency: F = 1.40, p = 0.268, interaction viral construct and frequency: F = 1.70, p = 0.21) (Fig. 3c) . The difference in AR indicates that the signal in the eYFP group consisted to a higher degree of light artifacts than in the ChR2-eYFP group.
To compare the glutamate concentrations evoked by stimulations at different frequencies and P rel , we calculated DC/t as measure of the evoked glutamate concentration independent of the duty cycle of the individual stimulation, using formula (3).
The ChR2-eYFP group possessed a significantly larger DC/t than the eYFP-group (two-way repeated measures ANOVA (viral construct, frequency), viral construct F = 9.62, p < 0.05). There was no difference in DC/t over the different frequencies (two-way repeated-measures ANOVA (viral construct, frequency), frequency: F = 0.47, p = 0.63, interaction: F = 2.08, p = 0.15) (Fig. 3d) . This led us to the conclusion that the amount of glutamate released per ms stimulation is largely independent of the frequency of the stimulation used, while the residual glutamate release per ms seen in the eYFP group is consistently lower than in the ChR2-eYFP group for all f stim .
To investigate differences between the glutamate clearance properties, we modeled the decay of C glu as a linear function in the initial phase (first 500 ms after cessation of the optogenetic stimulation) and as an exponential function in the late phase (500 ms following the initial phase). In the ChR2-eYFP group, the initial phase was closely modeled by a linear decay function (r 2 ≥ 0.89 for all frequencies) while in the eYFP group, the initial decay was modeled well for f stim = 20 and 40 Hz (r 2 ≥ 0.75) but only moderately for f stim = 10 Hz (r 2 = 0.52). In the late phase on the other hand, only the ChR2-eYFP group exhibited an exponential decay of C glu (r 2 ≥ 0.77), while no correlation was seen in the eYFP (r 2 ≤ 0.10) throughout the frequencies. The exact parameters for the initial and late phase are summarized in Supplementary Table S2 .
We performed a set of ex vivo control experiments in a model with light scattering properties comparable to brain tissue (Byron and Variano 2012; Yona et al. 2016) . To this end, recordings (n = 4) were performed in agarose (0.1% agarose in PBS 0.05 M) pieces warmed to 37°C, following the same protocols used in the in vivo experiments. Light stimulation did not evoke any detectable glutamate activity on the recordings electrodes in the ex vivo control experiments (data not shown).
In summary, optical stimulation at 0.2 to 0.8 mW led to glutamate concentrations between 0.3 and 0.9 lM in the ChR2-eYFP group with an AR of 3.6-5.4 and a DC/t of 4.1-5.5 nM/ms in protocol A. In the eYFP-group, this stimulation led to glutamate concentrations between 0.1 and 0.4 lM with an AR of 1.6-2.3 and a DC/t of 1.6-2.2 nM/ms.
Influence of laser power on evoked glutamate release As DC/t was similar throughout the frequencies, we hypothesized that the increases inĈ glu with higher frequencies were derived from their difference in P rel . To further test, this hypothesis, we designed a second stimulation protocol, protocol B, in which duty cycles were increased by prolonging t pulse to 15 ms for f stim = 10 Hz and to 10 ms for f stim = 20 Hz. Stimulation at f stim = 40 Hz was kept at a similar level as in protocol A with t pulse = 5 ms and t stim = 1 s (Fig. 4a) . Protocol B resulted in stimulation powers P rel of 0.6 mW for f stim = 10 Hz and 0.8 mW for f stim = 20 Hz and 40 Hz. Results forĈ 0.7 andĈ 0.25 in the ChR2-eYFP and eYFP groups are summarized in Supplementary Figure S3 . The change in glutamate concentration per millisecond laser stimulation ΔC/t was calculated asĈ glu divided by the product of t pulse , f stim and t stim . n = 7 ChR2-eYFP, n = 6 eYFP controls. Two-way repeated measures ANOVA: #p < 0.05, ##p < 0.01; Tukey HSD: **p < 0.01, ***p < 0.001.
The increase in t pulse in protocol B did not significantly alter the AR (two-way repeated-measures ANOVA, protocol: F = 0.37, p = 0.55; frequency: F = 0.80, p = 0.46; interaction: F = 1.99, p = 0.15) (Fig. 4b) or DC/t (two-way repeated-measures ANOVA, protocol: F = 1.09, p = 0.31; frequency: F = 2.38, p = 0.11; interaction: F = 1.41, p = 0.26) (Fig. 4c) compared to protocol A in the ChR2-eYFP group. As DC/t is stable in both protocols, the increase in t pulse for f stim = 10 Hz and 20 Hz led to significantly higherĈ glu in protocol B (two-way repeated-measures ANOVA, protocol: F = 47.52, p < 0.0001; frequency: F = 12.98, p < 0.001; interaction: F = 14.19, p < 0.0001) with glutamate concentrations reachingĈ glu = 0.83 AE 0.03 lM at f stim = 10 Hz (protocol B, t pulse = 15 ms) (Tukey HSD p < 0.001) and 1.07 AE 0.04 lM at f stim = 20 Hz (protocol B, t pulse = 10 ms) (Tukey HSD p < 0.0001) (Fig. 4d and e) . Clearance properties were not different between protocols A and B (Supplementary Table S2 ). There was no significant difference between f stim in protocol B. Results ofĈ glu , AR and DC/t for the eYFP group are summarized in Supplementary Figure S4 . This leads us to the conclusion that relative output power is of greater importance to the evoked glutamate release in optogenetic experiments than the frequency of the stimulation.
All in all, optogenetic stimulation ranging from 0.2 to 0.8 mW evoked glutamate concentrations of 0.3-1.1 lM throughout protocols A and B in the ChR2-eYFP group.
Discussion
In this study, we quantified optogenetically evoked glutamate release in the GP of transgenic Pitx2-Cre mice expressing ChR2-eYFP in projections of STN neurons and could segregate glutamate-based signals from photoelectric and photoelectrochemical artifacts in a reliable manner.
Previous studies have demonstrated the possibility to measure the intrinsically electrochemically active neurotransmitter dopamine in response to optogenetic stimulation utilizing voltammetry, amperometry and carbon fiber electrodes in the mouse striatum (Bass et al. 2010; Xu et al. 2015) . However, the ability to measure fast-acting, electrochemically inactive substances such as acetylcholine or glutamate within the brain, is itself a rather recent development with the establishment of constant-potential amperometry in conjunction with highly sensitive enzyme-coated microelectrodes (Burmeister et al. 2000; Burmeister and Gerhardt 2001) . Furthermore, the risk for light-induced artifacts due to optogenetic stimulation (Stujenske et al. 2015) makes it imperative to include several control parameters to be able to separate true neurotransmitter release from artifacts. These factors posed challenges for the development of techniques combining amperometry and optogenetics.
A recent study has provided first evidence for the possibility of measuring optogenetically evoked acetylcholine release (Gritton et al. 2016) and we have recently reported the possibility to record glutamate release in the nucleus accumbens following optogenetic stimulation Wang et al. 2017) . In this study, we address the clinically important projection from the STN to the GP and introduce a validated method to perform and analyze enzyme-based electrochemical recordings of glutamate upon optogenetic stimulation and to correct for artifacts.
When utilizing GluOx-coated microelectrodes with platinum recordings sites, photostimulation can lead to artifacts due to photoelectric currents (Han 2012) , and possibly photolysis of H 2 O 2 (Toki et al. 2015) . Photoelectric currents were reliably subtracted in our experiments using the selfreferencing approach with both glutamate-sensitive and sentinel channels on the same microelectrode (Burmeister and Gerhardt 2001; Day et al. 2006 ). The same is true for photoelectrochemical effects of H 2 O 2 photolysis (Toki et al. 2015) or light-induced redox processes (Kozai and Vazquez 2015) . By performing an additional cycle of stimulations at a holding potential of +0.25 V (Day et al. 2006) , we revealed a component not derived from GluOx activity. As the optic fiber was placed closer to the glutamate-sensitive channels than the sentinel channels, this remaining signal likely stems from remaining photoelectric or photoelectrochemical artifacts that are larger in the glutamate-sensitive channels than the sentinels. We corrected the glutamate signal measured at +0.7 V by subtracting the artifact obtained at +0.25 V. Alternatively, the position of the optic fiber could be altered to an equal distance from all recording sites of the microelectrode. Doing so would, however, also entail positioning the optic fiber on the front of the microelectrode, leading to direct illumination on the platinum recording sites, in turn increasing the magnitude of the artifact. We therefore see the multi-step artifact correction as advantageous, as it allows for increased flexibility in the positioning of the optic fiber in relation to the microelectrode while simultaneously minimizing the artifact generated. This approach will be of use for future electrochemical studies as it provides a means to further increase the accuracy of glutamate quantification in vivo.
During stimulation protocol A with a constant duty cycle, we examined a frequency-dependent increase in glutamate release in the low-lM range (0.3-0.9 lM at 0.2-0.8 mW). Protocol B resulted in a similar range of glutamate concentrations as protocol A (0.8-1.1 lM at 0.6-0.8 mW) and DC/t was similar (4-6 nM/ms) throughout all frequencies in both protocols. A previous study reported slightly higher glutamate release following 10 s electrical stimulation in rat STN with a frequency-dependent increase in glutamate concentration at a constant duty cycle (Lee et al. 2007) . Generally, the glutamate concentrations detected in our study are lower than with KCl stimulation or spontaneous cortical glutamate transients measured with amperometry (~1-3 lM) (Hascup et al. 2013; Mishra et al. 2015) . As the peak concentration of evoked glutamate in our study is in the lower physiological range and we furthermore used a low output power for our optogenetic stimulation, we see room for further increasing illumination strength and pulse length of the stimulation in future studies to evoke higher extracellular glutamate concentrations. The method presented in this study can thus be utilized to accurately evoke specific amounts of extracellular glutamate over a wide range of concentrations in the future.
To control for glutamate release originating from other sources than ChR2-activation, we measured glutamate concentrations in mice injected with a control virus expressing eYFP but no ChR2. Indeed, we could detect glutamate signals upon optic stimulation, although smaller in size. Even though light-induced heating (Kiyatkin et al. 2013; Stujenske et al. 2015) is minimized in our recordings, we cannot fully exclude a possible temperature effect on neuronal activity in the eYFP controls. Temperature changes on the electrode surface lead to fluctuations in the activity and sensitivity of the GluOx enzyme, which could contribute to this effect (S ßims ßek et al. 2016).
Independent of laser power and frequency, ChR2-expressing mice exhibited AR and DC/t that were nearly twice the size of the eYFP group's. As optical stimulation in ex vivo control experiments with comparable light scatter properties did not evoke any detectable signals, we hypothesize that the glutamate detected in the eYFP group could stem from nonChR2-derived glutamate release in the recording area. As a further factor, the ChR2-eYFP and eYFP groups differed in their clearance properties, with the ChR2-eYFP group adhering closely to a model of exponential decay for the late stage clearance, while this was not the case for the eYFP group. While neuronal activation caused by ChR2-activation is closely tied to the start and end of the optical stimulation (Zelena et al. 2017) , non-ChR2-derived glutamate in the eYFP group could follow a less stringent time-course, leading to the differences observed between the two groups.
The possibility of non-ChR2-derived glutamate release in optogenetic experiments is important to keep in mind also in experiments not directly measuring glutamate release, such as behavioral studies with optogentic interventions. For example, the inclusion of a ChR2-negative control group should be prioritized in these types of experiments to be able to make reliable claims on the origin and magnitude of the investigated optogenetic intervention.
To the best of our knowledge, this study is first to quantify evoked glutamate concentrations within the GP of mice. The ability to accurately quantify the glutamate concentration evoked by selective stimulation of STN neurons can prove useful for future research in relation to maladaptive changes occurring in Parkinson's disease. Current glutamate-focused approaches implemented experimentally to increase the physiological understanding of clinically applied deep brain highfrequency stimulations in Parkinson 0 s disease mainly rely on tonic concentration changes assessed by microdialysis (Windels et al. 2000; Lavian et al. 2013 ). Today 0 s microdialysis methodology lacks the temporal and spatial resolution that would be required for real-time quantification of evoked glutamate release following stimulation in specific areas of the GP. The technique presented in this study can serve to overcome these temporal and spatial restrictions, bridging the gap between long-term alterations of extracellular glutamate levels measured by microdialysis and electrophysiological assessment of neuronal activity in these areas.
In summary, this study introduces a novel method to quantify optogenetically evoked glutamate release in vivo. Furthermore, sources of light-induced artifacts in electrochemical recordings utilizing optogenetic stimulation were identified and we provide the means of correction for these artifacts. A collection of factors in addition to the pure amplitude of the signal, such as AR, DC/t and the decay kinetics of the signal, were described that can be used as identifiers of ChR2-derived and non-ChR2-derived signals. By providing a comprehensive framework for both recording and analysis, this study establishes in vivo detection and quantification of glutamate release following optogenetic stimulation and can thus advance real-time measurements of glutamate release in a wide variety of neuroscientific experiments in the future.
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